Cipla’s Pithampur unit faces setback as 8 USFDA observations lead to 7% dip in company’s stock.
Cipla’s stock price dropped by 7% to Rs 956.20 during intra-day trading on Monday, following the company’s announcement that the US Food and Drug Administration (FDA) had issued a Form 483 containing 8 observations.
The inspection was carried out to evaluate whether Cipla is following the current Good Manufacturing Practices (cGMP) standards.